Oric Pharmaceuticals Advances Lead Candidate to Phase 3, Extends Cash Runway into 2H 2028
ORIC has more than doubled off its 52-week low of $4.52.
Summary
Oric Pharmaceuticals reported Q1 2026 results, highlighted by the advancement of its lead candidate, rinzimetostat, to a Phase 3 trial and a significant extension of its cash runway into 2H 2028.
Key Events · Product Development and Regulatory · ORIC
-
Lead Candidate Advances to Phase 3
Oric Pharmaceuticals announced the selection of rinzimetostat's Recommended Phase 3 Dose (RP3D) and plans to initiate the Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC in 1H 2026.
-
Positive Clinical Data Reported
The company reported compelling rinzimetostat dose optimization data in mCRPC, supporting a potential best-in-disease profile with a differentiated safety profile and landmark rPFS rates consistent with competitors and superior to standard-of-care therapies.
-
Cash Runway Extended to 2H 2028
Cash and investments totaled $419.7 million as of March 31, 2026, which is expected to fund operations into the second half of 2028, extending beyond the anticipated primary endpoint readout from the first Phase 3 trial for rinzimetostat.
-
Significant Capital Raised via ATM
During the first quarter of 2026, the company raised $59.9 million in net proceeds through its at-the-market (ATM) program, contributing to the extended cash runway.
Analysis · ORIC · Life Sciences
This 8-K formally reports Oric Pharmaceuticals' Q1 2026 financial results and significant operational updates, following a news release on the same day. The company announced the selection of a Phase 3 dose for its lead candidate, rinzimetostat, and plans to initiate a global registrational trial in 1H 2026, a critical milestone for a clinical-stage biotech. Positive clinical data for rinzimetostat, suggesting a potential best-in-disease profile, further de-risks the program. Crucially, the company extended its cash runway into the second half of 2028, which is beyond the anticipated primary endpoint readout from the first Phase 3 trial. This financial stability, partly achieved through a substantial $59.9 million ATM capital raise during the quarter, provides a clear path for advancing its pipeline without immediate funding concerns.
At the time of this filing, ORIC was trading at $9.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $966.4M. The 52-week trading range was $4.52 to $14.93. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.